

Borat Sagdiyev, M.D.
1 Dreary Lane, Kazakhstan
(917) 884-0807
Email: bsagdiyev@att.net

SUMMARY STATEMENT

Healthcare analyst with four years of experience as a buy side analyst at both a hedge fund and broker dealer focused primarily on the biotechnology industry, but also on the specialty pharmaceutical and medical device sectors. Experienced in the fundamental analysis of healthcare companies including assessment of the prospects for new medical therapeutics from a scientific, regulatory and commercial perspective.

- Broad knowledge of several sectors of the healthcare industry.
- Understanding of the current regulatory environment and the key macro issues affecting companies within these sectors.
- History of success in assessing the likely outcome of key clinical trials of major products under development by biotechnology and specialty pharmaceutical companies. In 2005, successfully predicted the outcome of CV Therapeutics ERICA trial, Cardiome's ACT 3 trial and Renovis's SAINT-1 trial amongst others resulting in significant financial gains.
- Ability to interpret key clinical data presented at both academic meetings and published in the medical literature.

Have the ability to develop informed investment decisions by engaging extensive contacts in the medical and regulatory communities as well as in the pharmaceutical and biotechnology industries. Able to converse fluently with academic physicians and researchers engaged in clinical drug development given medical background and experience as a clinical researcher.

PROFESSIONAL EXPERIENCE

FINANCIAL SERVICES

Trivial Capital Management, New York, NY 2004-Present
Senior Healthcare Analyst

Analyze companies in the biotechnology and specialty pharmaceutical sectors as investments candidates for a long/short equity hedge fund. Work directly with the fund's portfolio manager in selecting stocks and managing the portfolio in these sectors.

- Perform due diligence on new drugs, medical devices and other medical technologies currently under development. Assess the commercial prospects for new medical therapeutics including market size, likely pricing and initial launch projections.
- Engage clinical researchers and physicians involved in clinical trials in order to predict and handicap their likely outcomes. Assess the trial design of ongoing clinical trials and interpret results, including the statistics, of clinical trials as they are reported.
- Calgon was top biotechnology company pick in 2005; the stock ended the year up approximately 140%.
- Develop strong relationships with senior management teams of companies within the above medical sectors in order to gain a fuller understanding of their operations and to further inform investment decisions.
- Engage regulatory consultants to determine the likely outcome of FDA regulatory decisions involving new drugs and other medical therapeutics.

Engulf, Devour & Co. LLC, New York, NY 2002-2004
Healthcare Analyst

Performed fundamental analysis of companies throughout the various healthcare sectors including biotechnology.

- Analyzed companies operation in all of the major healthcare sectors for a long term oriented multi-billion dollar long/short fund.
- One of top picks was Criotech which rose over 100%. Recognized the blockbuster potential of Criotech's Vaxin based on its ability to distinguish itself within the antidepressant market. Accurately predicted the positive FDA regulatory action on Recollectiona for the treatment of Alzheimer's Disease.
- Developed detailed financial models which incorporated projections based on assessment of prospects for newly introduced products.
- Interpreted prescription trends and other relevant data in order to make revenue projections for pharmaceuticals and other medical technologies in both the launch and post-launch phases of development.

MEDICAL

Private Practice Psychiatrist, New York, NY 2001-Present
Specialize in psychopharmacologic management and provide supportive psychotherapy.

New York Presbyterian, New York, NY 2001-2002
Attending Physician, Psychiatric Emergency Room
Clinical Instructor, Department of Psychiatry

Clinical Resources, South Orange, NJ 2000-2001
Private Practice Psychiatric/Research Physician

- Served as the Principal Investigator for a number of pharmaceutical company sponsored clinical trials investigating new antidepressant, anxiolytic and cognitive enhancing (anti-dementia) medications.
- Carried out clinical trial protocols including both the medical and psychiatric assessment of clinical trial subjects as well as the administration of study instrument measures.

Research Associates, Inc., New York, NY 1999-2000
Private Practice Psychiatrist/Research Physician

BOARD CERTIFICATIONS

Diplomate, American Board of Psychiatry and Neurology 2001-Present

STAFF PRIVILEGES

New York Presbyterian, New York, NY 1996-Present

PROFESSIONAL SOCIETIES

American Psychiatric Association 1997-Present

FINANCIAL CERTIFICATIONS

Series 7 Certification

PUBLICATIONS

General Hospital Psychiatry: Psychiatry, Medicine and Primary Care

Volume 28, Number 9, November/December 2000

Consulting-Liaison Psychiatry Database (2000 Update)

Part II: Nephrology Drug and Psychotropic Drug Interaction: Significance and Recommendations

EDUCATION AND TRAINING

Robert H. Smith Graduate School of Business, University of Maryland, Baltimore, MD

MBA in Healthcare Administration, June 2003

Smith/Doctor's Hospital Program in Healthcare Administration

Beta Gamma Sigma Honor Society

Beth Israel Medical Center, New York, NY

Resident in Psychiatry, July 1996-June 1999

Chief Resident, Psychiatric Emergency Room, 1998

Curie College of Medicine, Maplewood, NJ

Doctor of Medicine, June 1995

Dartmouth College, Hanover, NH

Bachelor of Arts in Psychology, May 1988

Board Senior National Honor Society

Psi Chi National Psychology Honor Society